[Interpretation of Chinese guidelines for diagnosis and treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (2022)].
作者信息
Xiong W J, Yi S H, Qiu L G
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Dec 14;43(12):986-991. doi: 10.3760/cma.j.issn.0253-2727.2022.12.003.
Abstract
摘要
相似文献
1
[Interpretation of Chinese guidelines for diagnosis and treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (2022)].[《淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断和治疗中国指南（2022年版）》解读]
Zhonghua Xue Ye Xue Za Zhi. 2022 Dec 14;43(12):986-991. doi: 10.3760/cma.j.issn.0253-2727.2022.12.003.
2
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.华氏巨球蛋白血症/淋巴浆细胞淋巴瘤，第 2.2024 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2024 Jan;22(1D):e240001. doi: 10.6004/jnccn.2024.0001.
3
[Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma/Walderström macroglobulinemia (2022)].[中国淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗指南（2022年版）]
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):624-630. doi: 10.3760/cma.j.issn.0253-2727.2022.08.002.
4
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM).《日本血液学会血液系统恶性肿瘤实用指南（2018 年）：II. 淋巴瘤 - 3. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症（LPL/WM）》
Int J Hematol. 2019 Nov;110(5):524-528. doi: 10.1007/s12185-019-02730-x. Epub 2019 Sep 7.
5
Waldenström Macroglobulinemia - 2020 Update on Management and Future Directions.华氏巨球蛋白血症——2020年管理与未来方向更新
Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S39-S41. doi: 10.1016/S2152-2650(20)30456-0.
6
[The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].[淋巴浆细胞淋巴瘤/华氏巨球蛋白血症的病理学及遗传背景]
Magy Onkol. 2017 Mar 8;61(1):6-11. Epub 2016 Nov 28.
7
[Clinical features of 16 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].16例淋巴浆细胞淋巴瘤/华氏巨球蛋白血症的临床特征
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1494-8.
8
Waldenström macroglobulinaemia: the key questions.华氏巨球蛋白血症：关键问题。
Br J Haematol. 2013 Aug;162(3):295-303. doi: 10.1111/bjh.12367. Epub 2013 May 8.
9
Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.淋巴浆细胞淋巴瘤和华氏巨球蛋白血症。
Arch Pathol Lab Med. 2013 Apr;137(4):580-5. doi: 10.5858/arpa.2012-0034-RS.
10
Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.淋巴浆细胞淋巴瘤和边缘区淋巴瘤。
Hematol Oncol Clin North Am. 2019 Aug;33(4):639-656. doi: 10.1016/j.hoc.2019.03.004. Epub 2019 Apr 30.
引用本文的文献
1
[The efficacy and safety of ibrutinib in the treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].依鲁替尼治疗淋巴浆细胞淋巴瘤/华氏巨球蛋白血症的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):755-760. doi: 10.3760/cma.j.cn121090-20240301-00077.
本文引用的文献
1
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis.华氏巨球蛋白血症一线治疗方案的疗效和安全性：系统评价和荟萃分析。
Blood Cancer J. 2023 Sep 7;13(1):140. doi: 10.1038/s41408-023-00916-5.
2
Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.免疫球蛋白重链基因库的特征及其与 LPL/WM 的临床相关性。
Blood Adv. 2022 Jul 12;6(13):4049-4059. doi: 10.1182/bloodadvances.2022007279.
3
Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤的临床特征与转归：一项瑞典淋巴瘤登记研究
Br J Haematol. 2022 Mar;196(6):1362-1368. doi: 10.1111/bjh.18002. Epub 2021 Dec 27.
4
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.华氏巨球蛋白血症：2021 年诊断、风险分层和治疗更新。
Am J Hematol. 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082.
5
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.伊布替尼单药治疗有症状、既往治疗的华氏巨球蛋白血症患者的长期随访。
J Clin Oncol. 2021 Feb 20;39(6):565-575. doi: 10.1200/JCO.20.00555. Epub 2020 Sep 15.
6
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.一项随机 3 期临床试验，比较 zanubrutinib 与 ibrutinib 在有症状的华氏巨球蛋白血症中的疗效：ASPEN 研究。
Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844.
7
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.泽布替尼治疗华氏巨球蛋白血症患者：3 年随访结果
Blood. 2020 Oct 29;136(18):2027-2037. doi: 10.1182/blood.2020006449.
8
How I treat Waldenström macroglobulinemia.我如何治疗华氏巨球蛋白血症。
Blood. 2019 Dec 5;134(23):2022-2035. doi: 10.1182/blood.2019000725.
9
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.无症状华氏巨球蛋白血症的进展风险分层。
J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.
10
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.华氏巨球蛋白血症：欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146.
Zotero 插件